CC 223

Drug Profile

CC 223

Alternative Names: CC-223

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Diffuse large B cell lymphoma; Non-small cell lung cancer
  • Preclinical Prostate cancer

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse event data from a phase Ib trial in Diffuse large B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 18 Sep 2015 CC 223 is still in phase I/II trials for Multiple myeloma, Non-Hodgkin's lymphoma and Solid tumours in the USA
  • 01 Dec 2013 Phase-I clinical trials in Diffuse large B cell lymphoma (combination therapy, second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top